Pasithea Therapeutics shares are trading higher after the company announced safety, tolerability, pharmacokinetic and preliminary efficacy data from the first 2 cohorts of patients in its Phase 1 clinical trial of PAS-004.
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics shares rose following positive data from its Phase 1 clinical trial of PAS-004, showing safety, tolerability, and preliminary efficacy.
September 26, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics' stock price increased due to positive results from its Phase 1 trial of PAS-004, indicating safety and preliminary efficacy.
The announcement of positive safety and efficacy data from the Phase 1 trial of PAS-004 is likely to boost investor confidence, leading to a short-term increase in KTTA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100